CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [*****] indicates the redacted confidential portions of this...Clinical Study Supply Agreement • February 26th, 2020 • Kamada LTD • Pharmaceutical preparations
This Clinical Study Supply Agreement (the “CSSA”) is made effective as of May 8th, 2019 (the “CSSA Effective Date”) by and between KAMADA Ltd., an Israeli company, with a principal place of business at 2 Holzman St., Science Park, P.O. Box 4081, Rehovot, 7670402, Israel (“KAMADA”) and PARI Pharma GmbH, with its registered office at Moosstrasse 3, 82319 Starnberg, Germany (“PARI”). In this CSSA, either PARI or KAMADA is referred to as a “Party,” and collectively as the “Parties.”
